Pharma BD Deal Intelligence

Pamplona Capital Management, LLP / PAREXEL International Corporation

2017 · Take-Private · $5.0B · Complete

Announcement Sentiment

Strongly positive

PAREXEL agreed to be taken private by Pamplona Capital for $88.10/share in cash, transaction valued at approximately $5B and representing a 27.9% premium over the May 5, 2017 unaffected closing price. PAREXEL provides full-service drug development outsourcing including clinical trials, regulatory consulting and reimbursement strategy. Transaction closed September 2017.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Assessment window: 5yr post-close.

Key facts

Announced Jun 20, 2017
Closed Sep 28, 2017
Deal value $5.0B
Deal type Take-Private
Therapeutic area Clinical research outsourcing
Indications Clinical research outsourcing
Key assets Global CRO services platform (clinical trials, regulatory, commercialization consulting)
Mechanism Contract research organization platform

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals